Assembly BiosciencesASMB +3.93%31 EV-to-EBIT is -24.02 as of Jul. 05, 2026. GuruFocus rates ASMB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 368 Biotechnology companies, Assembly Biosciences ranks worse than 271738.86% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Assembly Biosciences's Enterprise Value for the quarter that ended in Mar. 2026 was $216.89 Mil.
Assembly Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences EV-to-EBIT Related Terms
Assembly Biosciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Assembly Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's EV-to-EBIT falls into.
Assembly Biosciences's current Enterprise Value is $325.42 Mil.
Assembly Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (ASMB) has a EV-to-EBIT of -24.02 as of Jul. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #999999 out of 368 companies in the Biotechnology industry.
Is Assembly Biosciences' EV-to-EBIT too high?
Assembly Biosciences' current EV-to-EBIT is -24.02. Based on the distribution chart, Assembly Biosciences ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' EV-to-EBIT compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #999999 out of 368 companies for EV-to-EBIT. This places Assembly Biosciences in the lower half of its industry. The industry median EV-to-EBIT is 15.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.08, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Assembly Biosciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current EV-to-EBIT is -24.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current EV-to-EBIT of -24.02. The current EV-to-EBIT is -24.02. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current EV-to-EBIT is -24.02 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score
Get the complete analysis for ASMB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
